Azlocillin (BioDeep_00000006354)

 

Secondary id: BioDeep_00001868050

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

化学式: C20H23N5O6S (461.13689780000004)
中文名称: 阿洛西林
谱图信息: 最多检出来源 Homo sapiens(blood) 16.67%

分子结构信息

SMILES: CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
InChI: InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1

描述信息

Azlocillin is only found in individuals that have used or taken this drug. It is a semisynthetic ampicillin-derived acylureido penicillin.By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, azlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that azlocillin interferes with an autolysin inhibitor.
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

同义名列表

19 个代谢物同义名

(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Bayer brand OF azlocillin; Azlocillin bayer brand; Azlocillin sodium salt; Azlocillin, sodium; Sodium, azlocillin; Sodium azlocillin; Azlocillin sodium; Azlocillinum; Azlocilline; Azlocillin; Bay e 6905; Bay-e 6905; Azlocilina; Baye 6905; Securopen; Azlin



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

2 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Venkata Raveendra Pothineni, Hari-Hara S K Potula, Aditya Ambati, Venkata Vamsee Aditya Mallajosyula, Brindha Sridharan, Mohammed Inayathullah, Mohamed Sohail Ahmed, Jayakumar Rajadas. Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31. Scientific reports. 2020 03; 10(1):3798. doi: 10.1038/s41598-020-59600-4. [PMID: 32123189]
  • José A Murillo Pulgarín, Luisa F García Bermejo, Armando Carrasquero Durán. A fast and simple FIA-chemiluminescence method for the evaluation of Roselle flowers as scavenger of the free radicals generated by UV irradiated antibiotics. Journal of pharmaceutical and biomedical analysis. 2019 Feb; 164(?):630-635. doi: 10.1016/j.jpba.2018.11.004. [PMID: 30471635]
  • Aaron T Wolman, Michael R Gionfriddo, Gregory A Heindel, Paran Mukhija, Sarah Witkowski, Ajay Bommareddy, Adam L Vanwert. Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. Drug metabolism and disposition: the biological fate of chemicals. 2013 Apr; 41(4):791-800. doi: 10.1124/dmd.112.049569. [PMID: 23344796]
  • Aurijit Sarkar, Kelcey C Anderson, Glen E Kellogg. Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. European journal of medicinal chemistry. 2012 Jun; 52(?):98-110. doi: 10.1016/j.ejmech.2012.03.008. [PMID: 22483632]
  • Gloria Miller, Gregorio Begonia, Maria F T Begonia. Selected morphological characteristics, lead uptake and phytochelatin synthesis by coffeeweed (Sesbania exaltata Raf.) grown in elevated levels of lead-contaminated soil. International journal of environmental research and public health. 2011 06; 8(6):2401-17. doi: 10.3390/ijerph8062401. [PMID: 21776237]
  • Richard M Mariita, John A Orodho, Paul O Okemo, Claude Kirimuhuzya, Joseph N Otieno, Joseph J Magadula. Methanolic extracts of Aloe secundiflora Engl. inhibits in vitro growth of tuberculosis and diarrhea-causing bacteria. Pharmacognosy research. 2011 Apr; 3(2):95-9. doi: 10.4103/0974-8490.81956. [PMID: 21772752]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Ritu Aggarwal, Uma Chaudhary, Rama Sikka. Detection of Extended Spectrum β-lactamase Production Among Uropathogens. Journal of laboratory physicians. 2009 Jan; 1(1):7-10. doi: 10.4103/0974-2727.44423. [PMID: 21938241]
  • Chloë E James, Kozhinjampara R Mahendran, Alexander Molitor, Jean-Michel Bolla, Andrey N Bessonov, Mathias Winterhalter, Jean-Marie Pagès. How beta-lactam antibiotics enter bacteria: a dialogue with the porins. PloS one. 2009; 4(5):e5453. doi: 10.1371/journal.pone.0005453. [PMID: 19434239]
  • Franck E Dayan, J'Lynn Howell, Jeffrey D Weidenhamer. Dynamic root exudation of sorgoleone and its in planta mechanism of action. Journal of experimental botany. 2009; 60(7):2107-17. doi: 10.1093/jxb/erp082. [PMID: 19357432]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Humberto Guerra, Juan Carlos Palomino, Eduardo Falconí, Francisco Bravo, Ninoska Donaires, Eric Van Marck, Françoise Portaels. Mycobacterium ulcerans disease, Peru. Emerging infectious diseases. 2008 Mar; 14(3):373-7. doi: 10.3201/eid1403.070904. [PMID: 18325248]
  • Christophe Danelon, Ekaterina M Nestorovich, Mathias Winterhalter, Matteo Ceccarelli, Sergey M Bezrukov. Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophysical journal. 2006 Mar; 90(5):1617-27. doi: 10.1529/biophysj.105.075192. [PMID: 16339889]
  • G M Pacifici. Placental transfer of antibiotics administered to the mother: a review. International journal of clinical pharmacology and therapeutics. 2006 Feb; 44(2):57-63. doi: 10.5414/cpp44057. [PMID: 16502764]
  • Zh V Samsonova, O S Shchelokova, N L Ivanova, M Iu Rubtsova, A M Egorov. [Enzyme immunoassay of ampicillin in milk]. Prikladnaia biokhimiia i mikrobiologiia. 2005 Nov; 41(6):668-75. doi: . [PMID: 16358758]
  • Pekka Suomalainen, Christoffer Johans, Tim Söderlund, Paavo K J Kinnunen. Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. Journal of medicinal chemistry. 2004 Mar; 47(7):1783-8. doi: 10.1021/jm0309001. [PMID: 15027870]
  • A P MacGowan, K A Bedford, E Blundell, N M Brown, F Habib, J Hows, B Kirkpatrick, R J Korner, R R Slade, L O White. The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. The Journal of antimicrobial chemotherapy. 1994 Nov; 34(5):809-12. doi: 10.1093/jac/34.5.809. [PMID: 7706178]
  • X Z Li, D Ma, D M Livermore, H Nikaido. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy. 1994 Aug; 38(8):1742-52. doi: 10.1128/aac.38.8.1742. [PMID: 7986004]
  • A Gunneberg, M G Gillett, D J Goldie. A high serum concentration of azlocillin affects routine biochemical analyses. Annals of clinical biochemistry. 1993 May; 30 ( Pt 3)(?):329-30. doi: 10.1177/000456329303000319. [PMID: 8517619]
  • M N Dudley, J Blaser, D Gilbert, K H Mayer, S H Zinner. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. The Journal of infectious diseases. 1991 Sep; 164(3):499-506. doi: 10.1093/infdis/164.3.499. [PMID: 1908000]
  • R B Moss, E McClelland, R R Williams, B C Hilman, T Rubio, N F Adkinson. Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics. Reviews of infectious diseases. 1991 May; 13 Suppl 7(?):S598-607. doi: 10.1093/clinids/13.supplement_7.s598. [PMID: 2068466]
  • R B Moss. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. The Journal of allergy and clinical immunology. 1991 Jan; 87(1 Pt 1):78-88. doi: 10.1016/0091-6749(91)90215-a. [PMID: 1991925]
  • S L Barriere, D H Catlin, P L Orlando, A Noe, R W Frost. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrobial agents and chemotherapy. 1990 May; 34(5):823-6. doi: 10.1128/aac.34.5.823. [PMID: 2360821]
  • A Krupp, M Leuwer, H Schmidt, B Eberhardt. [The effect of continuous arteriovenous hemofiltration on the pharmacokinetics of azlocillin in anuric patients]. Der Anaesthesist. 1990 May; 39(5):275-8. doi: NULL. [PMID: 2192573]
  • P L Orlando, S L Barriere, J A Hindler, R W Frost. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects. Diagnostic microbiology and infectious disease. 1990 Mar; 13(2):93-7. doi: 10.1016/0732-8893(90)90091-9. [PMID: 2114954]
  • A A Firsov, V N Nasonov, S A Mura'veva, A A Kruglov. [Pharmacokinetics of azlocillin in critical conditions: an individualized schedule of drug administration in relation to anatomo-physiologic and pathologic factors]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 1989 Aug; 34(8):620-4. doi: NULL. [PMID: 2589904]
  • P Rosselli, L Marianelli, T Valenza, G Bartolozzi. [Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications]. La Pediatria medica e chirurgica : Medical and surgical pediatrics. 1989 Jul; 11(4):389-91. doi: NULL. [PMID: 2694104]
  • L Hjelte, A S Malmborg, B Strandvik. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis. The Journal of antimicrobial chemotherapy. 1989 Jun; 23(6):885-90. doi: 10.1093/jac/23.6.885. [PMID: 2503488]
  • R D Lander, R P Henderson, D R Pyszczynski. Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers. Antimicrobial agents and chemotherapy. 1989 May; 33(5):710-3. doi: 10.1128/aac.33.5.710. [PMID: 2751284]
  • A U Gerber, S Kozak, C Segessenmann, U Flückiger, T Bangerter, U Greter. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 1989 Mar; 8(3):233-7. doi: 10.1007/bf01965266. [PMID: 2496992]
  • C Thauvin, F Lecomte, I Le Boete, G Grise, J F Lemeland. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa. Infection. 1989 Jan; 17(1):31-4. doi: 10.1007/bf01643497. [PMID: 2493429]
  • W Schönfeld, J Knöller, K D Bremm, H Meier, W König. Concentration of azlocillin in human chondral tissue. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology. 1988 Mar; 267(4):537-40. doi: 10.1016/s0176-6724(88)80037-3. [PMID: 3381602]
  • R P Smith, H J Wilbur, C Bassey, A L Baltch. Azlocillin and mezlocillin concentration in human prostatic tissue. Chemotherapy. 1988; 34(4):267-71. doi: 10.1159/000238579. [PMID: 3208544]
  • R Voigt, I Weidt, S Schröder, A Brandstädt, G Peiker. [The pharmacokinetics of azlocillin after single and multiple intravenous injections during the third trimester]. Zentralblatt fur Gynakologie. 1988; 110(15):944-8. doi: NULL. [PMID: 3055753]
  • D M Yajko, P S Nassos, W K Hadley. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrobial agents and chemotherapy. 1987 Oct; 31(10):1579-84. doi: 10.1128/aac.31.10.1579. [PMID: 3501698]
  • W Kraus, J V Höltje. Two distinct transpeptidation reactions during murein synthesis in Escherichia coli. Journal of bacteriology. 1987 Jul; 169(7):3099-103. doi: 10.1128/jb.169.7.3099-3103.1987. [PMID: 3298212]
  • S Lowenbraun, N Fox, D Cunitz. Azlocillin, cephalothin, and tobramycin therapy in febrile solid tumor patients with chemotherapy-induced leukopenia. Cancer. 1987 Jul; 60(1):14-7. doi: 10.1002/1097-0142(19870701)60:1<14::aid-cncr2820600104>3.0.co;2-f. [PMID: 3581029]
  • A Whelton, R L Stout, P S Spilman, F A Delgado, A J Watson. The novel therapeutic implications of azlocillin's dose-dependent pharmacokinetics: contributing physiologic mechanisms and a prospective, cross-over designed trial. Journal of clinical pharmacology. 1987 Jul; 27(7):491-8. doi: 10.1002/j.1552-4604.1987.tb03055.x. [PMID: 3655000]
  • V V Berezhinskaia, G V Dolgova, G G Egorenko, T P Svinogeeva, L A Shtegel'man. [General toxic and organotropic properties of azlocillin in acute and chronic experiments]. Antibiotiki i meditsinskaia biotekhnologiia = Antibiotics and medical biotechnology. 1987 Jun; 32(6):453-60. doi: . [PMID: 3631939]
  • A Herrlinger, C Bornhof, R Kuehn. Antibiotic prophylaxis before extracorporeal shock wave lithotripsy by single-shot application of azlocillin. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1987 Jun; 6(2 Suppl):607-9. doi: NULL. [PMID: 3334645]
  • T T Rubio. Ciprofloxacin: comparative data in cystic fibrosis. The American journal of medicine. 1987 Apr; 82(4A):185-8. doi: . [PMID: 3555034]
  • G Steinkamp, M Lütge, U Wurster, J G Schulz-Baldes, H J Gröne, J H Ehrich. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. European journal of pediatrics. 1986 Dec; 145(6):526-31. doi: 10.1007/bf02429057. [PMID: 2880721]
  • H Michalsen, T Bergan. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases. Methods and findings in experimental and clinical pharmacology. 1986 Dec; 8(12):727-9. doi: NULL. [PMID: 3807473]
  • T A Tartaglione, L Nye, N Vishniavsky, W Poynor, R E Polk. Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers. Clinical pharmacy. 1986 Nov; 5(11):911-6. doi: NULL. [PMID: 3780161]
  • T T Rubio, C Shapiro. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. The Journal of antimicrobial chemotherapy. 1986 Nov; 18 Suppl D(?):147-52. doi: 10.1093/jac/18.supplement_d.147. [PMID: 3100490]
  • M S Collins, G C Tsay, R F Hector, R E Roby, J H Dorsey. Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo. Reviews of infectious diseases. 1986 Jul; 8 Suppl 4(?):S420-5. doi: 10.1093/clinids/8.supplement_4.s420. [PMID: 3092309]
  • A Tormo, J A Ayala, M A de Pedro, M Aldea, M Vicente. Interaction of FtsA and PBP3 proteins in the Escherichia coli septum. Journal of bacteriology. 1986 Jun; 166(3):985-92. doi: 10.1128/jb.166.3.985-992.1986. [PMID: 3011758]
  • D E Johnson, B Thompson. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. The American journal of medicine. 1986 May; 80(5C):53-8. doi: . [PMID: 3636060]
  • A S Bayer, I K Blomquist, K S Kim. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy. 1986 May; 17(5):641-9. doi: 10.1093/jac/17.5.641. [PMID: 2941403]
  • P A Colaizzi, R E Polk, W J Poynor, A C Raffalovich, E A Cefali, L A Beightol. Comparative pharmacokinetics of azlocillin and piperacillin in normal adults. Antimicrobial agents and chemotherapy. 1986 May; 29(5):938-40. doi: 10.1128/aac.29.5.938. [PMID: 3729353]
  • E Rubinstein, Z Mark, Y Samra, M Alkan, S Berger. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1986 Apr; 5(2):75-82. doi: . [PMID: 2939966]
  • M Papapetropoulou, E Giannoulaki, K Kastamonitis, T Siorokou, J Legakis. Azlocillin and serum uric acid. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1986 Apr; 5(2):113-5. doi: NULL. [PMID: 3708717]
  • S H Zinner, J Blaser. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. The Journal of antimicrobial chemotherapy. 1986 Mar; 17 Suppl A(?):1-5. doi: 10.1093/jac/17.suppl_a.1. [PMID: 3086275]
  • M Wenk, F Follath. Azlocillin serum levels on repetitive dosage in patients with normal and abnormal renal function. Chemotherapy. 1986; 32(3):205-8. doi: 10.1159/000238417. [PMID: 3709269]
  • V Holá, L Polívková, L Novák. Pharmacokinetics of azlocillin after intramuscular application. Czechoslovak medicine. 1986; 9(3):166-9. doi: NULL. [PMID: 3095077]
  • C E Nord, T Bergan, S Aase. Impact of azlocillin on the colon microflora. Scandinavian journal of infectious diseases. 1986; 18(2):163-6. doi: 10.3109/00365548609032323. [PMID: 3704564]
  • R A Woolf, J R Koup, A L Smith, B C Hilman, D Goldmann, J Williams-Warren. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis. Clinical pharmacy. 1985 Nov; 4(6):664-9. doi: NULL. [PMID: 4075734]
  • W Schönfeld, J Knöller, K D Bremm, W König. Degradation of azlocillin in human serum. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology. 1985 Oct; 260(2):254-9. doi: 10.1016/s0176-6724(85)80122-x. [PMID: 3002076]
  • R W Strunk, J C Gratz, R Maserati, W M Scheld. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrobial agents and chemotherapy. 1985 Sep; 28(3):428-32. doi: 10.1128/aac.28.3.428. [PMID: 2934021]
  • C B Wilson, J R Koup. Clinical pharmacology of extended-spectrum penicillins in infants and children. The Journal of pediatrics. 1985 Jun; 106(6):1049-56. doi: 10.1016/s0022-3476(85)80267-5. [PMID: 3889255]
  • H Lagast, M Husson, J Klastersky. Comparative in-vitro activities of azlocillin, ticarcillin and ticarcillin plus clavulanic acid against Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy. 1985 May; 15(5):633-6. doi: 10.1093/jac/15.5.633. [PMID: 3924883]
  • V P Pozdniakova, S M Kuznetsova, A N Lobuseva, I P Fomina. [Methods of evaluating the efficacy of combinations of aminoglycosides with penicillins and their value for the possibility of predicting the therapeutic effect in patients]. Antibiotiki i meditsinskaia biotekhnologiia = Antibiotics and medical biotechnology. 1985 May; 30(5):369-75. doi: NULL. [PMID: 3927835]
  • A P Johnson, S V Scoper, F L Woo, D R Caldwell, W J George. Azlocillin levels in human tears and aqueous humor. American journal of ophthalmology. 1985 Apr; 99(4):469-72. doi: 10.1016/0002-9394(85)90015-7. [PMID: 3985084]
  • R Voigt, R Patsch, S Schröder, G Peiker, A Brandstädt. [Pharmacokinetic studies of azlocillin in pregnancy]. Zeitschrift fur Geburtshilfe und Perinatologie. 1985 Mar; 189(2):88-90. doi: NULL. [PMID: 4013451]
  • H R Stutman, K M Parker, M I Marks. Potential of moxalactam and other new antimicrobial agents for bilirubin-albumin displacement in neonates. Pediatrics. 1985 Feb; 75(2):294-8. doi: . [PMID: 3155833]
  • M F Parry. The safety and tolerance of azlocillin. Arzneimittel-Forschung. 1985; 35(8):1292-4. doi: . [PMID: 4074446]
  • H J Zeiler, K G Metzger, P Schacht, K Grohe. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy. Drugs under experimental and clinical research. 1985; 11(5):343-50. doi: NULL. [PMID: 2941263]
  • E Haen, J Remien, E Richter, U Frank, D Adam. [The effect of infusion rate on pharmacokinetic parameters of azlocillin and mezlocillin]. Arzneimittel-Forschung. 1985; 35(5):864-8. doi: NULL. [PMID: 4026911]
  • R Voigt, S Schröder, G Peiker. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy. 1985; 31(6):417-24. doi: 10.1159/000238369. [PMID: 3908007]
  • A Dalhoff, G Stübner. Comparative analysis of the antimicrobial action of polymorphonuclear leucocytes in vitro, ex vivo and in vivo. The Journal of antimicrobial chemotherapy. 1985 Jan; 15 Suppl A(?):283-91. doi: 10.1093/jac/15.suppl_a.283. [PMID: 3980331]
  • N Martini, M Agostini, G Barlocco, L Bozzini, L Castellani, A Messori, G Scroccaro, G Mastella. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis. Journal of clinical and hospital pharmacy. 1984 Dec; 9(4):303-9. doi: 10.1111/j.1365-2710.1984.tb01091.x. [PMID: 6396321]
  • A J Falkowski, R J Creger. Hydroxylamine technique for in vitro prevention of penicillin inactivation of tobramycin. Antimicrobial agents and chemotherapy. 1984 Nov; 26(5):643-6. doi: 10.1128/aac.26.5.643. [PMID: 6393865]
  • H M Just, C P Speicher, M Bassler, F D Daschner. [Bactericidal activity of azlocillin against Pseudomonas aeruginosa in human serum]. Infection. 1984 Nov; 12(6):405-6. doi: 10.1007/bf01645226. [PMID: 6440867]
  • T Lenz, H Haller. [Athrombocytosis during cefotaxim-azlocillin combination therapy]. Deutsche medizinische Wochenschrift (1946). 1984 Sep; 109(37):1423-4. doi: NULL. [PMID: 6090089]
  • J T Summersgill, L G Harrod, M J Raff. Azlocillin and cefonicid penetration into bone enhanced by probenecid. Antimicrobial agents and chemotherapy. 1984 Sep; 26(3):292-4. doi: 10.1128/aac.26.3.292. [PMID: 6508259]
  • A G Skar, T Midtvedt, O Dahl. Comparison of the in vitro activity of azlocillin and carbenicillin against 856 clinical bacterial isolates. NIPH annals. 1984 Jun; 7(1):13-9. doi: NULL. [PMID: 6493580]
  • L R Peterson, D N Gerding, J A Moody, C E Fasching. Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model. Antimicrobial agents and chemotherapy. 1984 May; 25(5):545-52. doi: 10.1128/aac.25.5.545. [PMID: 6329087]
  • S B Calderwood, C C Tung, E Jackson. Measurement of levels of aminoglycosides and vancomycin in serum in the presence of new beta-lactam antibiotics. Journal of clinical microbiology. 1984 May; 19(5):707-9. doi: 10.1128/jcm.19.5.707-709.1984. [PMID: 6330168]
  • J A Bosso, B A Saxon, J J Herbst, J M Matsen. Azlocillin pharmacokinetics in patients with cystic fibrosis. Antimicrobial agents and chemotherapy. 1984 May; 25(5):630-2. doi: 10.1128/aac.25.5.630. [PMID: 6732230]
  • A Penketh, M E Hodson, H Gaya, J C Batten. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax. 1984 Apr; 39(4):299-304. doi: 10.1136/thx.39.4.299. [PMID: 6426075]
  • A Thabaut, A Philippon, M Meyran. [Comparative effect of beta-lactam activity on Pseudomonas aeruginosa as a function of resistance phenotypes]. Presse medicale (Paris, France : 1983). 1984 Mar; 13(13):768-71. doi: . [PMID: 6231592]
  • E Singlas, C Haegel. [Clinical pharmacokinetics of azlocillin]. Presse medicale (Paris, France : 1983). 1984 Mar; 13(13):788-96. doi: NULL. [PMID: 6231596]
  • H Millart, H Choisy, D Lamiable, C Choisy. [Bone and blood levels of azlocillin after intra-arterial injection in the dog]. Presse medicale (Paris, France : 1983). 1984 Mar; 13(13):802-4. doi: NULL. [PMID: 6231598]
  • H B Drugeon, M Pannier, A L Courtieu. [Pharmacokinetics of azlocillin in the burn patient]. Presse medicale (Paris, France : 1983). 1984 Mar; 13(13):805-7. doi: NULL. [PMID: 6231599]
  • J P Fillastre, G Humbert, A Leroy, M Godin. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients]. Presse medicale (Paris, France : 1983). 1984 Mar; 13(13):797-801. doi: NULL. [PMID: 6231597]
  • D Kampf, K Borner, M Möller, M Kessel. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function. Clinical pharmacology and therapeutics. 1984 Feb; 35(2):214-20. doi: 10.1038/clpt.1984.29. [PMID: 6319069]
  • I von Zabern, H Przyklenk, R Nolte, W Vogt. Effect of different penicillin derivatives on complement components in human serum. International archives of allergy and applied immunology. 1984; 75(2):164-72. doi: 10.1159/000233608. [PMID: 6469387]
  • R Haag. Fosfomycin, piperacillin, azlocillin. Correlation between therapeutic response of mice infected with Pseudomonas aeruginosa and in vitro data. Chemotherapy. 1984; 30(4):227-36. doi: 10.1159/000238273. [PMID: 6430654]
  • A Weber, K E Opheim, K Wong, A L Smith. High-pressure liquid chromatographic quantitation of azlocillin. Antimicrobial agents and chemotherapy. 1983 Nov; 24(5):750-3. doi: 10.1128/aac.24.5.750. [PMID: 6660850]
  • A S Malmborg, H Alfredsson, B Strandvik. Azlocillin in cystic fibrosis. Israel journal of medical sciences. 1983 Nov; 19(11):1001-3. doi: NULL. [PMID: 6662681]
  • D Fogel, L Farfel, A Miskin, B M Mogilner. Comparison between the combination of azlocillin-gentamicin and ampicillin-gentamicin in the treatment of a nursery population. Israel journal of medical sciences. 1983 Nov; 19(11):1009-15. doi: NULL. [PMID: 6662683]
  • M Bassler, W Depuis, E Utz, H M Just, F D Daschner. Effect of azlocillin and piperacillin in subinhibitory and inhibitory concentrations on Staphylococcus aureus and Pseudomonas aeruginosa in broth, in serum and in the presence of human polymorphonuclear leukocytes. European journal of clinical microbiology. 1983 Oct; 2(5):439-44. doi: 10.1007/bf02013901. [PMID: 6416838]
  • J A Ernst, E R Sy. Effect of azlocillin on uric acid levels in serum. Antimicrobial agents and chemotherapy. 1983 Oct; 24(4):609-10. doi: 10.1128/aac.24.4.609. [PMID: 6651284]
  • J D McCue, P Gal, R C Pearson. Interference of new penicillins and cephalosporins with urine glucose monitoring tests. Diabetes care. 1983 Sep; 6(5):504-5. doi: 10.2337/diacare.6.5.504. [PMID: 6400711]
  • B Balischewski, R Kiessig, W Thal, H Köditz. [Antibacterial activities of amicacin, azlocillin and cefotaxim in bronchial secretion and serum of children]. Kinderarztliche Praxis. 1983 Sep; 51(9):437-40. doi: NULL. [PMID: 6317938]
  • D A Kafetzis, D C Brater, J E Fanourgakis. Materno-fetal transfer of azlocillin. The Journal of antimicrobial chemotherapy. 1983 Aug; 12(2):157-62. doi: 10.1093/jac/12.2.157. [PMID: 6619053]
  • H Lode, V Madey, G Dzwillo, K Borner, P Koeppe. Serum bactericidal activity and kinetics of azlocillin and moxalactam after single and combined administration. The Journal of antimicrobial chemotherapy. 1983 May; 11 Suppl B(?):121-6. doi: 10.1093/jac/11.suppl_b.121. [PMID: 6413481]
  • F A Delgado, R L Stout, A Whelton. Pharmacokinetics of azlocillin in normal renal function: single and repetitive dosing studies. The Journal of antimicrobial chemotherapy. 1983 May; 11 Suppl B(?):79-88. doi: 10.1093/jac/11.suppl_b.79. [PMID: 6619035]
  • A Whelton, R L Stout, F A Delgado. Azlocillin kinetics during extracorporeal haemodialysis and peritoneal dialysis. The Journal of antimicrobial chemotherapy. 1983 May; 11 Suppl B(?):89-95. doi: 10.1093/jac/11.suppl_b.89. [PMID: 6619036]